Psyence Biomedical Announces Production Of GMP-Compliant, High-Purity Ibogaine Hydrochloride Derives From Naturally Extracted Source In Africa

Benzinga · 4d ago

Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement.

Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard pharmaceutical format for this compound. Conversion to the hydrochloride salt improves stability, solubility, purity, and dosing precision, aligning the material with regulated medical, research, and pharmaceutical development requirements.